Pharmaceutical company · OTSKY

Otsuka
clinical trial
pipeline

Registry checked

Published

Sibeprenlimab is linked to 6 distinct active studies, with 3 Phase 2, 3 Phase 3. Ulotaront is linked to 5 distinct active studies, with 5 Phase 3.

Phase 3 study NCT07173478 in Atopic Dermatitis (AD) lists estimated primary completion in December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

38active trials
as lead sponsor
  • Phase 17
  • Phase 25
  • Phase 320
  • Phase 40
  • Phase not recorded6

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

1611 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved earlier by 110 days

2029-04-17 (estimated)2028-12-28 (estimated)
17 Apr 202928 Dec 2028

Phase 2b Open-Label Repeat Kidney Biopsy Study

NCT06740526 · ClinicalTrials.gov
Recorded by ComplyRx
28 Oct 2026
Registry last updated
27 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-051010021
2026-10-060000000
2026-10-070000000
2026-10-080000221
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-141000011
2026-10-150000000
2026-10-160100011
2026-10-171100022
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-211000122
2026-10-220000000
2026-10-230100011
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270100121
2026-10-281110031
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals552041611 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Sibeprenlimab

voyxact

6
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Focal Segmental Glomerulosclerosis · IgA Nephropathy · Immunoglobulin A Nephropathy
Next primary completion
13 March 2027 · estimated
Open drug

Ulotaront

Canonical investigational asset

5
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Generalized Anxiety Disorder · Schizophrenia
Next primary completion
Not reported
Open drug

Centanafadine

Canonical investigational asset

4
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Attention Deficit Hyperactivity Disorder (ADHD) · Attention-Deficit Hyperactivity Disorder(ADHD)
Next primary completion
Aug 2027 · estimated
Open drug

Repinatrabit

Canonical investigational asset

4
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy Volunteers · Phenylketonuria · Phenylketonuria (PKU)
Next primary completion
01 November 2027 · estimated
Open drug

Difamilast

adquey

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Atopic Dermatitis (AD)
Next primary completion
Dec 2026 · estimated
Open drug

Bedaquiline

SIRTURO

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Multidrug-Resistant Pulmonary Tuberculosis · Rifampicin-Resistant Pulmonary Tuberculosis
Next primary completion
Not reported
Open drug

31 of 38 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 31 of 38 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Otsuka trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
Difamilast

NCT07173478

Phase 3 · Not yet recruiting

Trial source and qualifications

A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: Oct 2025 · estimated
    Primary completion: Dec 2026 · estimated
    Study completion: Dec 2026 · estimated

    2021202220232024202520262027202820292030
    A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
    Difamilast

    NCT07184645

    Phase 3 · Not yet recruiting

    Trial source and qualifications

    A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    No eligible observations recorded in the inspected period.

      Start: Sept 2025 · estimated
      Primary completion: Feb 2027 · estimated
      Study completion: Feb 2027 · estimated

      2021202220232024202520262027202820292030
      EnVISage
      Sibeprenlimab

      NCT06928142

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

      3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      3 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 23 Apr 2025 · actual
        Primary completion: 13 Mar 2027 · estimated
        Study completion: 04 Jun 2027 · estimated

        2021202220232024202520262027202820292030
        A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
        Centanafadine XR

        NCT07759154

        Phase 3 · Recruiting

        Trial source and qualifications

        A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        Up to three verified eligible observations in the bounded history window.

        • status flip · Recorded 2026-09-14 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 01 Sept 2026 · actual
        Primary completion: 27 May 2027 · estimated
        Study completion: 27 May 2027 · estimated

        2021202220232024202520262027202820292030
        A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
        Centanafadine

        NCT07086313

        Phase 3 · Recruiting

        Trial source and qualifications

        A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 03 Sept 2025 · actual
          Primary completion: Aug 2027 · estimated
          Study completion: Aug 2027 · estimated

          2021202220232024202520262027202820292030
          A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
          Centanafadine

          NCT07087327

          Phase 3 · Recruiting

          Trial source and qualifications

          A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 16 Sept 2025 · actual
            Primary completion: Aug 2027 · estimated
            Study completion: Aug 2027 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 22 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 2 actual primary completions, 0 untyped primary completions, 1 past estimates, 0 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            11

            active trials in Psychiatry & Addiction

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Psychiatry & Addiction11 trials
            • Renal & Urology6 trials
            • Immunology & Inflammation4 trials
            • Metabolic/Endocrine/Nutrition4 trials
            • Dermatology2 trials
            • Oncology2 trials
            • Infectious Disease1 trials
            • Unmapped7 trials
            • Healthy volunteers1 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Otsuka Pharmaceutical operating scope covers 528 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Otsuka Pharmaceutical Co., Ltd.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion. This is the Otsuka Pharmaceutical operating scope. Taiho and US Astex are excluded. UK Astex lacks a supported canonical identity and is unrepresented.

            ClinicalTrials.gov

            Attribution coverage

            529 distinct registry candidates produced 528 accepted studies. 0 mapped to other owners, 1 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            498 scoped records have indexed enrichment and 30 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-11-01T00:57:16.735Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 489d254192681bab4afd39f78dac3022d50c9530145ea66b83d3b937eaf9d27b.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 528 mapped lead-sponsored clinical studies across all statuses. 498 have indexed enrichment, 30 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.